Increasing developments and availability of new substrates have significantly expanded the applications of horseradish peroxidase. Vendors are emphasizing the development of advanced substrates such as chemiluminescent and fluorogenic compounds that generate strong and stable signals. These innovative substrates are offering enhanced sensitivity, thereby enhancing the performance and capabilities of horseradish peroxidase-based assays across diverse fields. For instance, in October 2022, Neogen introduced a ready-to-use chemiluminescent substrate under its K-Blue product line that offers simpler workflow through eliminating mixing errors.
Additionally, integration of horseradish peroxidase-based assays with microfluidics has paved a new development in lab-on-a-chip devices and microfluidic paper-based analytical devices (microPADs). According to the 2023 study published by Elsevier, microPADs represent an emerging platform for point of care testing, offering a wide range of potential applications, from medical diagnostics to environmental monitoring. Horseradish peroxidase is among the most used enzymes across these applications. As a result, the growing adoption of advanced lab-on-a-chip devices and microPADs is further expected to fuel the demand for horseradish peroxidase globally.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
The global horseradish peroxidase market size was valued at USD 64.1 million in 2023 and is anticipated to showcase growth at 7.5% CAGR from 2024
The immunoassays segment held 65.7% of the market share in 2023 and will grow rapidly through 2032, attributed to increasing use of horseradish peroxidase-based antibody assays across diagnostic testing requiring high sensitivity.
North America horseradish peroxidase market accounted for 40.6% share in 2023 and is predicted to reach USD 47.8 million by 2032, attributed to increasing demand of horseradish peroxidase-based assays for diagnostic testing.
Abcam Limited, Abnova Corporation, BBI Solutions, Bio-rad Laboratories, Inc, Creative Enzymes, Enzo Life Sciences, Inc, F. Hoffman-La Roche Ltd., Faizyme Laboratories (Pty) Ltd, GenScript, and Merck KGaA among others.